Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.

Tiek DM, Rone JD, Graham GT, Pannkuk EL, Haddad BR, Riggins RB.

Sci Rep. 2018 May 8;8(1):7222. doi: 10.1038/s41598-018-25588-1.

2.

Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method.

Wathieu H, Issa NT, Fernandez AI, Mohandoss M, Tiek DM, Franke JL, Byers SW, Riggins RB, Dakshanamurthy S.

Oncotarget. 2017 Oct 9;8(54):92926-92942. doi: 10.18632/oncotarget.21669. eCollection 2017 Nov 3.

3.

Estrogen-related receptor β (ERRβ) - renaissance receptor or receptor renaissance?

Divekar SD, Tiek DM, Fernandez A, Riggins RB.

Nucl Recept Signal. 2016 Jun 21;14:e002. doi: 10.1621/nrs.14002. eCollection 2016. Review.

4.

Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRβ2) splice variant in breast cancer.

Heckler MM, Zeleke TZ, Divekar SD, Fernandez AI, Tiek DM, Woodrick J, Farzanegan A, Roy R, Üren A, Mueller SC, Riggins RB.

Oncotarget. 2016 Jul 26;7(30):47201-47220. doi: 10.18632/oncotarget.9719.

Supplemental Content

Support Center